Antispasmodic use of hyoscine during pregnancy (scopolamine, hyoscine butylbromide)
Hyoscine is administered during pregnancy mainly for short-term obstetric or peri-obstetric symptom management that targets smooth-muscle spasm or anticholinergic effects. Hyoscine butylbromide is used intrapartum as an antispasmodic intended to affect labor progress, particularly the active phase. Scopolamine is used peri-operatively in pregnancy as an antiemetic, most commonly around cesarean delivery under anesthesia. [1] [2] [3]
Hyoscine butylbromide (hyoscine n-butylbromide) for labor spasm and labor progress
Hyoscine butylbromide is an antispasmodic with parasympatholytic/anticholinergic activity used as a “cervical spasmolytic” in intrapartum care. [4] Hyoscine butylbromide has been studied for shortening the duration of the labor active phase. [4] [5] A systematic review and meta-analysis of randomized trials reported that hyoscine butylbromide shortened the active phase of labor without adverse effects in the included studies. [5] A systematic review focused on hyoscine butylbromide and labor progress concluded that study results vary and that maternal and neonatal adverse event reporting was limited in many trials. [6]
Scopolamine for prevention of perioperative nausea and vomiting
Scopolamine is used to prevent nausea and vomiting, including in perioperative settings associated with anesthesia and opioid analgesia. [3] Product labeling for transdermal scopolamine includes an indication for use in pregnancy only when the potential benefit justifies the potential risk to the fetus, with an obstetric adjunctive use described for delivery by cesarean section. [3] Clinical use in pregnancy for this purpose is consistent with the established antiemetic role of scopolamine in perioperative care. [2] [3]
Safety and clinical decision-making constraints
Hyoscine butylbromide contains limited data in pregnant women in product information, with pregnancy use stated as not recommended as a precautionary measure in some regulatory summaries. [1] When scopolamine is used in pregnancy for antiemetic purposes, product labeling emphasizes benefit–risk justification for fetal exposure. [3]
Practical clinical contexts where administration occurs
Common obstetric contexts for hyoscine administration include intrapartum management where antispasmodic effects are intended to modify labor duration, particularly the active phase. [4] [5] Common obstetric contexts for scopolamine include perioperative antiemetic prophylaxis when anesthesia is used, such as around cesarean delivery. [2] [3]
Key mechanism targets
Hyoscine butylbromide targets smooth-muscle spasm with anticholinergic/antispasmodic pharmacology, which is the basis for its intrapartum investigation. [4] Scopolamine targets the nausea/vomiting pathway via anticholinergic effects, which is the basis for its perioperative antiemetic use. [2] [3]